Pathophysiological impact of the adhesion G protein-coupled receptor family

Abstract excerpt

G protein-coupled receptors (GPCRs) represent one of the most targeted drug classes in the human genome, accounting for greater than 40% of all Food and Drug Administration-approved drugs. However, the second-largest family of GPCRs, known as adhesion GPCRs (aGPCR), have yet to serve as a clinical target despite increasing evidence of their physiological and pathological functions, which suggests an opportunity...

Topics

Join the communities discussing this publication.

• Monoclonal and Polyclonal Antibodies Research
• Neuropeptides and Animal Physiology
• Receptor Mechanisms and Signaling